AI assistant
GALECTIN THERAPEUTICS INC — Director's Dealing 2018
Jun 13, 2018
33422_dirs_2018-06-12_95acce30-62f8-429a-8df6-6bf71380fd91.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2018-06-08
Reporting Person: CZIRR JAMES C (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-06-08 | Common Stock | S | 50000 | $5.64 | Disposed | 3069786 | Indirect |
| 2018-06-08 | Common Stock | S | 60000 | $6.08 | Disposed | 3009786 | Indirect |
Footnotes
F1: Common shares should pursuant to a trading plan pursuant to Rule 10b5-1. Price represents the gross sales price less commissions and brokerage fees.
F2: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. 10X Capital Management, LLC disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.